Medicamen Biotech Live Share Price Today, Share Analysis and Chart

Name: Medicamen Biotech Ltd.: Is Infosys Ltd. worth buying?
Item: Medicamen Biotech Ltd.
Rating: 2.388458375
Author: Trendlyne DVM scores

Mid-range Performer

about

Medicamen Biotech is engaged in Generic Finished Dosage Forms, Oncology Formulations and Research & Development services to cater to the needs of the Global Pharmaceuticals Industry.

394.75 -10.35 (-2.55%)

33.41% Fall from 52W High

20,237

NSE+BSE Volume

NSE 15 Dec, 2025 3:31 PM (IST)

Loading... You have run out of DVM views!

Subscribe now to see details

Medium Financial Strength

- / 100

Mid Valuation

- / 100

Technically Neutral

47.4 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

No estimates available

Medicamen Biotech Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Is Medicamen Biotech Ltd. worth buying?

39 Votes:

Buy 76.92%

Sell 17.95%

Hold 5.13%

Medicamen Biotech Live Share Price Today, Share Analysis and Chart

Medicamen Biotech is engaged in Generic Finished Dosage Forms, Oncology Formulations and Research & Development services to cater to the needs of the Global Pharmaceuticals Industry.

33.41% Fall from 52W High

SWOT Analysis

Medicamen Biotech Live Price Chart